Loading...

Emerging Markets And Digital Transformation Will Enable Long-Term Stability

Published
23 Feb 25
Updated
15 Jun 26
Views
1k
15 Jun
UK£45.73
AnalystConsensusTarget's Fair Value
UK£50.27
9.0% undervalued intrinsic discount
Loading
1Y
26.3%
7D
2.3%

Author's Valuation

UK£50.279.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 15 Jun 26

Fair value Increased 8.80%

BATS: Future Returns Will Reflect Smokeless Transition Progress And Dividend Dependability

Analysts have raised their fair value estimate for British American Tobacco from £46.21 to £50.27. This reflects updated assumptions around discount rates, profit margins and future P/E expectations.

What's in the News

  • British American Tobacco has updated its growth outlook for smokeless products, now guiding to mid-teens sales growth for these categories, supported by vapour and nicotine pouch demand in the US, according to recent news reports.
  • The company continues to push toward a predominantly smokeless business by 2035, with a focus on expanding its vapour and nicotine pouch ranges as traditional cigarette volumes soften. (Source: recent news coverage)
  • Recent reports highlight investor focus on vape and nicotine pouch growth, with attention on planned 2026 launches of flavored Vuse products and new Velo pouches in the US market. (Source: recent news coverage)
  • British American Tobacco is continuing its share buyback program while aiming to keep full year revenue and underlying operating profit growth within its stated target ranges. Recent commentary points to outcomes at the lower end of those ranges due to cost and geopolitical pressures. (Source: recent news coverage)
  • The company has announced that Dragos Constantinescu will become Chief Financial Officer from 1 September 2026, returning to British American Tobacco after senior roles at Asahi Breweries. Javed Iqbal will remain as Interim CFO until then and will continue as Director, Digital & Information after the transition. (Source: company announcement)

Valuation Changes

  • Fair Value: revised from £46.21 to £50.27, representing a modest upward reset in the estimated share valuation.
  • Discount Rate: moved from 8.95% to 8.68%, indicating a slightly lower required return in the valuation model.
  • Revenue Growth: adjusted from 3.36% to 3.24%, reflecting a small reduction in the long term sales growth assumption.
  • Profit Margin: refined from 29.33% to 29.52%, suggesting a slightly higher expected profitability level.
  • Future P/E: updated from 15.22x to 16.38x, indicating a higher assumed earnings multiple in the forecast period.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion of reduced-risk products and innovation in emerging markets supports global growth, margin improvement, and earnings resilience.
  • Digital transformation and cost efficiency drive capital allocation, cash generation, and sustained shareholder returns.
  • Regulatory, market, and societal pressures threaten revenue stability, margin growth, and long-term business sustainability as BAT transitions from traditional cigarettes to newer product categories.

Catalysts

About British American Tobacco
    Provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States.
What are the underlying business or industry changes driving this perspective?
  • The rapid growth and further penetration of Modern Oral (Velo) and Heated Products, especially in emerging markets with rising disposable incomes, positions BAT well to tap into geographic revenue diversification and stabilize global volumes, supporting top-line growth in the medium to long term.
  • Strong uptake and premiumization of reduced-risk new category products (Modern Oral, Heated, and Vapour), combined with successful innovation rollouts (Velo Plus, glo Hilo, Vuse Ultra), are driving higher contribution margins and gross margins, setting the stage for structural net margin and earnings expansion as these products scale.
  • Digital transformation, operational streamlining, and targeted cost savings programs (e.g., Fit2Win, global supply chain efficiencies) are releasing capital for reinvestment in high-return growth opportunities and innovation, protecting operating margins and supporting future free cash flow growth.
  • Proactive adaptation to evolving regulatory environments (e.g., greater enforcement on illicit vapour, prioritizing science-backed engagement) and strategic resource allocation to profitable/favorable markets underpin management's ability to safeguard market share and drive resilience in both existing and new product segments, with the expected effect of stabilizing earnings.
  • Ongoing strong cash generation, disciplined deleveraging, and a commitment to progressive dividends and share buybacks enhance total shareholder return potential and underpin long-term financial flexibility, likely supporting sustained EPS growth and valuation re-rating as execution continues.
British American Tobacco Earnings and Revenue Growth

British American Tobacco Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming British American Tobacco's revenue will grow by 3.2% annually over the next 3 years.
  • Analysts assume that profit margins will shrink from 30.0% today to 29.5% in 3 years time.
  • Analysts expect earnings to reach £8.3 billion (and earnings per share of £3.98) by about June 2029, up from £7.7 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as £7.3 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.4x on those 2029 earnings, up from 13.0x today. This future PE is greater than the current PE for the US Tobacco industry at 12.7x.
  • Analysts expect the number of shares outstanding to decline by 0.94% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.68%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Escalating regulatory risk and fiscal headwinds in key markets-such as flavor bans, strict enforcement inconsistency, and increased excise taxes (e.g., Bangladesh, Australia, Canada, and Malaysia)-continue to impact legal product availability and sales, particularly in vapour, which could erode BAT's revenues and operating margins over time.
  • Persistent illicit trade in vapour and combustible products, especially in the U.S. and Canada, undermines BAT's legal market share and limits its ability to grow volumes and revenues from both traditional and new category products, thereby putting pressure on revenue growth and earnings stability.
  • Ongoing secular declines in combustible cigarette volumes, despite near-term stabilization and pricing offsets, represent a fundamental risk to BAT's main revenue base (still >70% from combustibles), potentially leading to long-term revenue contraction and margin pressure as regulatory and public health pressure increases.
  • High and rising investment in new categories (Modern Oral, Heated, Vape) is required to offset declines in traditional products, yet these segments face intense competition, evolving regulatory hurdles, and inconsistent execution-risking lower-than-expected returns on investment, reduced profitability, and more volatile earnings.
  • ESG-related investor aversion and growing health consciousness may limit BAT's access to certain pools of institutional capital, suppress share valuations, and shrink the overall addressable market over the longer term, affecting both net margins and enterprise value.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of £50.27 for British American Tobacco based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £57.5, and the most bearish reporting a price target of just £36.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £28.2 billion, earnings will come to £8.3 billion, and it would be trading on a PE ratio of 16.4x, assuming you use a discount rate of 8.7%.
  • Given the current share price of £46.31, the analyst price target of £50.27 is 7.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on British American Tobacco?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives